The company is an important supplier of disease control and nucleic acid testing products. It has made very important contributions to the prevention and control of H7N9 avian influenza virus in 2013, Ebola virus outbreak in West Africa in 2014 and novel coronavirus pneumonia outbreak in 2020. In the field of clinical testing, the company is an important supplier of microecological testing products for female lower reproductive tract.
Jiangsu Shuoshi Biotechnology Co., Ltd. was founded in 2010 and is located in Taizhou China Pharmaceutical City, Jiangsu Province, a high-tech park. With molecular diagnostic technology as the core, Shuoshi Biology is a national high-tech enterprise that integrates diagnostic reagents, instruments, and third-party medical inspection services.
In terms of products, the company has multiple fluorescence quantitative PCR, enzyme chemistry and other modern biological technology platforms, engaged in disease prevention and control, female reproductive tract microecological testing and tumor screening and other fields of product development, production and sales.

After the announcement of the new coronavirus virus gene sequence, Shuoshi Bio successfully developed a new coronavirus pneumonia (2019) nucleic acid detection kit in only 3 days, becoming the first new coronavirus pneumonia detection reagent certified by Jiangsu statutory inspection agency.
The first time to assist the local epidemic detection and prevention work in Wuhan, donation value 10 million virus nucleic acid detection reagents and instruments, plan to be donated in batches to local hospitals in need, and will be added according to the development of the epidemic.